CDKN2A and pancreatic adenocarcinoma: In FPC families, CDKN2A mutations were identified in 21.4% of cases, and in patients with both pancreatic adenocarcinoma and melanoma, germline CDKN2A mutations (I49S and M53I) were found, with I49S showing impaired binding to CDK4 [45,46].